Business
Final Results
Final Results.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 8439B\n Sareum Holdings PLC\n 13 October 2020\n \n \n \n \n Sareum Holdings PLC \n \n \n (\"Sareum\" or the \"Company\")\n \n FINAL RESULTS FOR THE YEAR ENDED 30 JUNE 2020\n \n Cambridge, UK, 13 October 2020 - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, announces its results for the year ended 30 June 2020.\n The Company will be holding a presentation to investors on 16 October 2020 at 10.00 a.m. via the Investor Meet Company platform - please click on this link to register to attend: https://www.investormeetcompany.com/sareum-holdings-plc/register-investor.\n The Company expects to publish its Annual Report and Accounts, along with the Notice of the Company's Annual General Meeting, in November 2020.\n OPERATIONAL HIGHLIGHTS (including post-period updates)\n Proprietary Programmes - Selective TYK2/JAK1 Inhibitors in Autoimmune Diseases and Cancer\n SDC-1801 (autoimmune diseases)\n \n · A new formulation specifically designed to deliver higher exposure levels of SDC-1801 has recently been developed by the Company, which is suitable for progressing into the further toxicology studies needed prior to applying to investigate SDC-1801 in human trials.\n \n · SDC-1801 has demonstrated excellent tolerability in initial toxicology studies in rodents. A formulation that is predicted to deliver a therapeutic dose level has also been identified.\n \n · If progress is successful, the application to commence first human trials is expected to be made during Q1 2021.\n SDC-1802 (cancer immunotherapy)\n \n · \n Formulation work for oral dosing of SDC-1802 is complete and toxicology studies and further manufacturing work are planned over the coming months. \n \n \n · \n In October 2019, Sareum presented new findings showing that SDC-1802, dosed orally as a monotherapy and in combination with chemotherapy, significantly reduces tumour growth in models of solid tumours and blood cancers.\n \n \n · \n In October 2020, the Company received a Notice of Allowance for its US patent covering SDC-1802, the grant of which will complete the patent protection of this compound in all major territories. \n \n TYK2/JAK1 Inhibitors for treating symptoms of Covid-19\n \n · A grant application has ...